Psoriatic Arthritis

Berlin, Germany—The biologic drug ustekinumab (Stelara), which is al­ready approved for use in patients with moderate-to-severe plaque psoriasis, has demonstrated promise in treating psoriatic arthritis, according to data from the late-stage PSUMMIT-1 clinical trial.
By David Hawk Berlin, Germany—Results of an analysis presented by Chureen T. Carter, PharmD, MS, Associate Director of Health Economics and Outcomes Research at Janssen Scientific Affairs, Horsham, PA, and colleagues at the 2012 European League Against Rheumatism Congress indicate that during the time period of the introduction of biologic agents for the treatment of psoriatic arthritis, the direct healthcare costs related to psoriatic arthritis management rose from approximately $3500 annually to an annual expenditure exceeding $16,000.
Page 4 of 4
Results 31 - 32 of 32
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology